Cargando…

The CHEK 2 GENE mutations and the risk of Gastric cancer

Detalles Bibliográficos
Autores principales:	Teodorczyk, Urszula, Cybulski, Cezary, Jakubowska, Anna, Starzyńska, Teresa, Ławniczak, Małgorzata, Ferenc, Katarzyna, Marlicz, Krzysztof, Banaszkiewicz, Zbigniew, Wiśniowski, Rafał, Lubiński, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287430/ http://dx.doi.org/10.1186/1897-4287-10-S1-A10

Ejemplares similares

Mutations and polymorphisms of genes moderate increase in gastric cancer risk
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland
por: Jakubowska, Anna, et al.
Publicado: (2010)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
por: Ławniczak, Małgorzata, et al.
Publicado: (2016)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

The influence of selenium concentration and variations in selenoprotein genes on the CHEK2-dependent cancers
por: Gupta, Satish, et al.
Publicado: (2015)

Survival of bladder or renal cancer in patients with CHEK2 mutations
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

The prevalence of CHEK2 and CYP1B1 mutations/polymorphisms in urinary bladder cancer
por: Banaszkiewicz, Monika, et al.
Publicado: (2012)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Nuclear Pedigree Criteria for the Identification of Individuals Suspected to Be at Risk of an Inherited Predisposition to Gastric Cancer
por: Gawdis-Wojnarska, Beata, et al.
Publicado: (2004)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
por: Domagala, Pawel, et al.
Publicado: (2015)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

Iron and breast cancer risk
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Magnesium as a diagnostic marker of cancer
por: Marciniak, Wojciech, et al.
Publicado: (2015)

Cyclin D1 and CHEK2 polymorphic variants as low risk susceptibility alleles in DTC patients
por: Hryhorowicz, Szymon, et al.
Publicado: (2015)

Selenium and the risk of cancer of the lung and larynx. A case-control study from a region with low selenium
por: Jaworska, Katrzyna, et al.
Publicado: (2012)

Selenium as diagnostic marker of cancers
por: Jaworska-Bieniek, Katarzyna, et al.
Publicado: (2015)

Zinc as diagnostic marker of cancers
por: Kaczmarek, Katarzyna, et al.
Publicado: (2015)

Iron as diagnostic marker of cancer
por: Sukiennicki, Grzegorz, et al.
Publicado: (2015)

Folic acid and breast cancer risk
por: Durda, Katarzyna, et al.
Publicado: (2012)

Microelements as risk factors for cancer of the lung and larynx
por: Jaworska-Bieniek, Katrzyna, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility
por: Trubicka, Joanna, et al.
Publicado: (2010)

A case of carotid body paraganglioma and haemangioblastoma of the spinal cord in a patient with the N131K missense mutation in the VHL gene
por: Majchrzak, Krzysztof, et al.
Publicado: (2011)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

CHEK2 Mutation in Patient with Multiple Endocrine Glands Tumors. Case Report
por: Szeliga, Anna, et al.
Publicado: (2020)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9vne43foetqdntr1ce44ikvno